Market Place
Sourcing Support
Gilead liver disease med still delivers ahead of FDA verdict
20 May 2024 //
FIERCE BIOTECH
Gilead Announces Expiration of Waiting Period for CymaBay Tender Offer
11 Mar 2024 //
BUSINESSWIRE
CymaBay Announces EMA Accepts for Review the MAA for Seladelpar
04 Mar 2024 //
GLOBENEWSWIRE
CymaBay Reports Fourth Quarter & Year Ended December 31, 2023 Financial Results
28 Feb 2024 //
GLOBENEWSWIRE
CymaBay board pushed for 50 cent top up to Gilead`s $32.50 offer
26 Feb 2024 //
FIERCE BIOTECH
The New England Journal Publishes Positive Phase 3 of CymaBay`s Seladelpar
21 Feb 2024 //
PR NEWSWIRE
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20 Feb 2024 //
GLOBENEWSWIRE
Cymabay Therapeutics Investor Alert By The Former Attorney General Of Louisiana
16 Feb 2024 //
BUSINESSWIRE
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
13 Feb 2024 //
PRESS RELEASE
CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar
12 Feb 2024 //
PR NEWSWIRE
CymaBay Therapeutics to Participate in Upcoming Investment Conferences
31 Jan 2024 //
GLOBENEWSWIRE
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16 Jan 2024 //
GLOBENEWSWIRE
Published Data Showes Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement
03 Jan 2024 //
PR NEWSWIRE
CymaBay to Present at the 42nd Annual JP Morgan Healthcare Conference 2024
02 Jan 2024 //
GLOBENEWSWIRE
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18 Dec 2023 //
GLOBENEWSWIRE
CymaBay Submits NDA for Seladelpar for Treatment of Primary Biliary Cholangitis
15 Dec 2023 //
PR NEWSWIRE
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17 Nov 2023 //
GLOBENEWSWIRE
CymaBay Announces an Oral Presentation of Seladelpar Phase 3 Pivotal Results
13 Nov 2023 //
PR NEWSWIRE
CymaBay Reports Third Quarter and Nine Months Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
CymaBay Therapeutics to Present at Upcoming Investment Conferences
06 Nov 2023 //
GLOBENEWSWIRE
CymaBay Announces Publication of Two-year Safety Results of Seladelpar
01 Nov 2023 //
GLOBENEWSWIRE
CymaBay Therapeutics to Report Third Quarter of 2023 Financial Results
31 Oct 2023 //
GLOBENEWSWIRE
Seladelpar Granted Breakthrough Therapy Designation for Biliary Cholangitis
23 Oct 2023 //
GLOBENEWSWIRE
CymaBay™s Ph 3 Data Evaluating Seladelpar for Biliary Cholangitis to be Featured
18 Oct 2023 //
GLOBENEWSWIRE
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16 Oct 2023 //
GLOBENEWSWIRE
CymaBay Initiates AFFIRM, a Phase 3b/4 Study Evaluating the Effect of Seladelpar
21 Sep 2023 //
GLOBENEWSWIRE
CymaBay Therapeutics to Present at the Cantor Global Healthcare Conference
15 Sep 2023 //
GLOBENEWSWIRE
CymaBay Announces Closing of Upsized $258.7M Public Offering of Common Stock
14 Sep 2023 //
GLOBENEWSWIRE
CymaBay Announces Proposed $150 Million Public Offering of Common Stock
11 Sep 2023 //
GLOBENEWSWIRE
CymaBay Announces Pricing of Upsized $225M Public Offering of Common Stock
11 Sep 2023 //
GLOBENEWSWIRE
CymaBay`s Seladelpar Achieves Significance in Phase 3 in Biliary Cholangitis
07 Sep 2023 //
PR NEWSWIRE
CymaBay to Host Investor Call to Share Results from Phase 3 Trial of Seladelpar
06 Sep 2023 //
GLOBENEWSWIRE
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
28 Aug 2023 //
GLOBENEWSWIRE
CymaBay Initiates Phase 3 Placebo-Controlled, Randomized Study of Seladelpar
10 Aug 2023 //
PR NEWSWIRE
CymaBay Reports Q2 and Six Months Ended June 30, 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
CymaBay to Report Second Quarter of 2023 Financial Results on August 10, 2023
03 Aug 2023 //
GLOBENEWSWIRE
CymaBay Presents Data Showing Seladelpar Treatment in (PBC) C
21 Jun 2023 //
PR NEWSWIRE
CymaBay to Present New Data Highlighting Seladelpar`s Unique Activity
07 Jun 2023 //
PR NEWSWIRE
CymaBay Reports 1Q 2023 FYR Results and Provides Corporate Update
15 May 2023 //
GLOBENEWSWIRE
CymaBay Therapeutics to Report First Quarter of 2023 FYR on Monday, May 15, 2023
10 May 2023 //
GLOBENEWSWIRE
CymaBay Names Harish Shantharam Chief Financial Officer
09 May 2023 //
GLOBENEWSWIRE
CymaBay Announces Publication of Results FromENHANCE, Ph 3 Study of Seladelpar
21 Apr 2023 //
GLOBENEWSWIRE
CymaBay Therapeutics to Present at the H.C. Wainwright BioConnect Investor
17 Apr 2023 //
GLOBENEWSWIRE
CymaBay to Present at H.C. Wainwright BioConnect Investor Conference at NASDAQ
17 Apr 2023 //
PRESS RELEASE
CymaBay Reports Fourth Quarter and Year Ended December 31 2022 Financial Results
16 Mar 2023 //
GLOBENEWSWIRE
CymaBay to Report Fourth Quarter and Full Year 2022 Financial Results
09 Mar 2023 //
GLOBENEWSWIRE
CymaBay Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare
01 Mar 2023 //
GLOBENEWSWIRE
CymaBay to Present at the SVB Securities Global Biopharma Conference
06 Feb 2023 //
GLOBENEWSWIRE
CymaBay Announces Closing of Public Offering of Common Stock
30 Jan 2023 //
GLOBENEWSWIRE
CymaBay looks to raise $85M as liver drug`s PhIII readout looms
24 Jan 2023 //
ENDPTS
CymaBay Announces Pricing of Public Offering of Common Stock
24 Jan 2023 //
GLOBENEWSWIRE
CymaBay Announces Proposed Public Offering of Common Stock & Pre-Funded Warrants
23 Jan 2023 //
GLOBENEWSWIRE
CymaBay Announces Collaboration with Kaken to Develop Seladelpar
08 Jan 2023 //
GLOBENEWSWIRE
CymaBay Reports 3Q and Nine Months Ended Sep 30, 2022 FYR
14 Nov 2022 //
GLOBENEWSWIRE
CymaBay Presents Additional Analyses from Clinical Studies of Seladelpar
04 Nov 2022 //
GLOBENEWSWIRE
CymaBay Therapeutics to Present at Upcoming Investment Conferences
03 Nov 2022 //
GLOBENEWSWIRE
CymaBay Announces Appointment of Charles McWherter, Ph.D. to CSO
01 Nov 2022 //
GLOBENEWSWIRE
CymaBay Appoints Charles McWherter to CSO and President of R&D
01 Nov 2022 //
BIOSPACE
CymaBay Therapeutics Hosting Virtual Analyst Day on September 22
14 Sep 2022 //
GLOBENEWSWIRE
CymaBay Therapeutics to Present at the H.C. Wainwright 24th AnnualGIC
06 Sep 2022 //
GLOBENEWSWIRE
